OPKO Health, Inc. (OPK) is one of the best healthcare stocks under $30, operating in diagnostics, pharmaceuticals, and therapies. They are making progress with an EBV vaccine in partnership with Merck and developing a GLP-1 pipeline for metabolic disorders. The company is also selling certain assets to Labcorp to focus on core diagnostics and pharmaceuticals.

The FDA approved a key update to OPKO’s 4KScore Test, expanding its role in primary care for prostate cancer risk assessment. The sale of certain BioReference assets to Labcorp will enhance operational efficiency. While OPK shows potential as an investment, certain AI stocks may offer greater upside potential with less downside risk.

OPKO Health, Inc. (OPK) continues to advance with an EBV vaccine and GLP-1 pipeline, while streamlining diagnostics. The company’s work with Merck and Entera Bio, as well as ModeX in oncology, shows promising developments. The sale of certain assets to Labcorp will allow OPKO to focus on core operations.

Read more at Yahoo Finance: OPKO Health (OPK) Advances EBV Vaccine and GLP-1 Pipeline While Streamlining Diagnostics